Fact Check: Edited BioNTech CEO clip resurfaces with false vaccine claim
The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...
BioNTech SE ADR rises Tuesday, outperforms market
The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...
Private equity firms who hold 43% of BioNTech SE (NASDAQ:BNTX) gained 6.8%, institutions profited as well
Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...
BioNTech Target of Unusually High Options Trading (NASDAQ:BNTX)
BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...
FiercePharma4d
BioNTech inks settlements with NIH, Penn in COVID-19 vaccine royalty disputes
The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
The votes are in on CHOP’s resident union | Philly Health Insider
Also, Penn settled a lawsuit with the German drug manufacturer BioNTech, which, with Pfizer, made the COVID vaccine using ...
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and ...
Pharmaceutical Technology2d
Trastuzumab pamirtecan by BioNTech for Solid Tumor: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Morgan Stanley Sticks to Its Buy Rating for BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
Pharmaceutical Technology2d
BNT-325 by BioNTech for Malignant Mesothelioma: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...